ivaltinostat
Phase 2- Indications
- Metastatic pancreatic ductal adenocarcinoma
Company intelligence / Profile preview
CG Pharmaceuticals
Orinda, California, United Statescgpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
CG Pharmaceuticals is conducting a Phase 1b/2 clinical trial for ivaltinostat in metastatic pancreatic cancer. The Phase 1b study has been completed with 28 patients across 3 dose levels, showing a manageable safety profile with primarily grade 1-2 adverse events. Phase 2 enrollment is ongoing with completion expected in 2025 and final clinical study report by mid-2026[1][3].
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on CG Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG Pharmaceuticals.